These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17902731)

  • 1. Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: a real clinical threat?
    Mignogna MD; Fortuna G; Ruoppo E; Adamo D; Leuci S; Fedele S
    Am J Clin Dermatol; 2007; 8(5):291-9. PubMed ID: 17902731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety.
    Gürcan HM; Jeph S; Ahmed AR
    Am J Clin Dermatol; 2010; 11(5):315-26. PubMed ID: 20642294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects.
    Svecova D
    Australas J Dermatol; 2016 May; 57(2):141-4. PubMed ID: 26581165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study.
    Letko E; Bhol K; Foster SC; Ahmed RA
    Curr Eye Res; 2000 Aug; 21(2):646-54. PubMed ID: 11148601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
    Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
    J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
    Arnold DF; Burton J; Shine B; Wojnarowska F; Misbah SA
    Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy.
    Ahmed AR
    Expert Opin Investig Drugs; 2004 Aug; 13(8):1019-32. PubMed ID: 15268639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
    Daoud Y; Amin KG; Mohan K; Ahmed AR
    Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune mucocutaneous blistering diseases in the south of Italy: a 25-year retrospective study on 169 patients.
    Calabria E; Fortuna G; Aria M; Mignogna MD
    J Oral Pathol Med; 2020 Aug; 49(7):672-680. PubMed ID: 32531813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study.
    Mignogna MD; Leuci S; Fedele S; Ruoppo E; Adamo D; Russo G; Pagliuca R
    Am J Clin Dermatol; 2008; 9(5):323-31. PubMed ID: 18717608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production.
    Bhol KC; Desai A; Kumari S; Colon JE; Ahmed AR
    Clin Immunol; 2001 Aug; 100(2):172-80. PubMed ID: 11465946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
    Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
    Sami N; Bhol KC; Razzaque Ahmed A
    Clin Immunol; 2002 Jan; 102(1):59-67. PubMed ID: 11781068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
    Letko E; Miserocchi E; Daoud YJ; Christen W; Foster CS; Ahmed AR
    Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan.
    Takeuchi M; Ito S; Nakamura M; Kawakami K
    Paediatr Drugs; 2018 Dec; 20(6):585-591. PubMed ID: 30345488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.